Vancouver, Canada – April 14, 2026 – Augurex Life Sciences Corp., a leader in the development of autoimmune-based diagnostics, today announced that it has been named a semifinalist in the 2026 Disruptive Technology Award competition presented by the Association for Diagnostics and Laboratory Medicine (ADLM).
Augurex was recognized for SPINEstat® (Anti-14-3-3eta Multiplex), a first-in-class biomarker-based diagnostic test designed to support earlier identification of axial spondyloarthritis (axSpA) and help differentiate inflammatory disease from mechanical back pain. Diagnostic delay remains a significant challenge in axSpA, and SPINEstat® was developed to address this unmet clinical need by supporting more informed diagnostic decision-making earlier in the disease course.
The ADLM Disruptive Technology Award is a highly competitive program that evaluates emerging diagnostic technologies with the potential to meaningfully advance laboratory medicine and impact patient care. The competition brings together scientific, clinical, and laboratory medicine experts to assess innovations based on scientific rigor, clinical relevance, and transformative potential. Selection as a semifinalist reflects the strength of SPINEstat®’s underlying science and its relevance to real-world diagnostic challenges in inflammatory disease.
This recognition underscores Augurex’s continued focus on developing biomarker-driven diagnostic solutions that address unmet clinical needs and support improved clinical decision-making across autoimmune and inflammatory diseases.
Augurex appreciates the recognition from ADLM and congratulates the other companies selected as semifinalists in this year’s competition.
For more information about the ADLM Disruptive Technology Award, visit:
https://meeting.myadlm.org/conference-program/disruptive-technology-award/contestants
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s 14-3-3eta blood test, available as JOINTstat® in Canada and in Great Britain, is an important tool in the diagnosis and management of rheumatoid arthritis. Analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex test, approved as SPINEstat® in Canada and Great Britain, expands Augurex’s portfolio of autoimmune diagnostic solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, which if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.